FibroBiologics (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.
"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly," said FibroBiologics Chief Executive Pete O'Heeron.
Hamid Khoja, the biotechnology company's chief scientific officer said, "unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly."
Price: 2.41, Change: -0.09, Percent Change: -3.75
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。